ADHD vs. Sleep Apnea: The Misdiagnosis That Sends Patients in the Wrong Direction

Why This Differential Matters

The patient presenting with daytime inattention, distractibility, irritability, and the subjective experience of cognitive sluggishness has, in current practice, a high probability of being evaluated for ADHD. In children, the same constellation — fidgetiness, behavioral disinhibition, school underperformance, emotional reactivity — is similarly likely to lead to ADHD evaluation. In both age groups, the differential diagnosis includes a condition that is far less often considered at the initial evaluation: obstructive sleep apnea.

This is not an obscure differential. The estimated prevalence of obstructive sleep apnea in adults in the United States ranges from 9% to 38% depending on the population studied and the threshold used, and the condition is markedly underdiagnosed. In children, OSA prevalence is estimated at 1-5%, with adenotonsillar hypertrophy as the leading anatomical contributor. When these prevalences are layered onto the prevalence of ADHD — approximately 5-10% in children and 4-5% in adults — the population of patients who could plausibly carry either or both diagnoses is large.

The clinical question is not whether OSA and ADHD overlap. They do, in two distinct ways. First, OSA produces cognitive and behavioral symptoms that phenotypically resemble ADHD, creating diagnostic confusion. Second, OSA and ADHD genuinely co-occur at rates well above what would be expected by chance. Both phenomena require clinicians evaluating attention complaints to think systematically about sleep — and require ADHD specialists to integrate sleep screening into the standard workup. This article walks through both problems, the evidence behind them, and the practical screening and treatment framework that follows.

The Symptom Overlap: Why OSA Looks Like ADHD

The mechanistic explanation for the symptomatic overlap between OSA and ADHD is sleep fragmentation. Obstructive sleep apnea, by definition, produces repeated episodes of partial or complete upper airway collapse during sleep, leading to oxyhemoglobin desaturation, microarousals from sleep, and a fragmented sleep architecture with reduced slow-wave and REM sleep. The downstream consequences are predictable and well characterized.

Chronic sleep fragmentation produces:

• Impaired sustained attention — vigilance, focus on protracted tasks, and resistance to distraction all degrade after sleep loss, and the degradation is cumulative
• Working memory deficits — the ability to hold and manipulate information in mind, which is highly sensitive to sleep quality
• Executive dysfunction — planning, inhibition, set-shifting, and decision-making all suffer with chronic sleep restriction
• Emotional dysregulation — irritability, reduced frustration tolerance, mood lability, and reactive affect
• Behavioral disinhibition in children — paradoxically, sleep-deprived children frequently appear more hyperactive, more impulsive, and more behaviorally disorganized, not less
• Daytime sleepiness — though this is more characteristic of OSA than ADHD, it is not invariably present, particularly in children who often manifest sleep deprivation as hyperactivity rather than overt drowsiness

This symptom list is also, with minor variation, the symptom list for ADHD. The Diagnostic and Statistical Manual criteria for ADHD include difficulty sustaining attention, distractibility, working memory complaints, executive dysfunction, fidgetiness, and emotional reactivity. The overlap is not coincidental — it reflects the fact that the prefrontal cortex and its subcortical projections, which mediate the cognitive functions affected in ADHD, are also among the brain regions most vulnerable to sleep disruption.

The clinical implication is straightforward: a patient presenting with cognitive symptoms cannot be assumed to have ADHD without a sleep history. The history is what separates a primary attentional disorder from a secondary attentional syndrome driven by an unrecognized sleep disorder. Without that history, the diagnosis is incomplete, and the treatment plan is at risk of being incorrect.

Pediatric OSA: The Adenotonsillectomy Evidence

In pediatric practice, the most common cause of obstructive sleep apnea is adenotonsillar hypertrophy. The adenoids and palatine tonsils enlarge through early childhood, peaking in size between approximately ages 3 and 7, before involuting in later childhood and adolescence. When the lymphoid tissue is sufficiently large to compromise the upper airway during sleep, the result is sleep-disordered breathing — ranging from primary snoring through obstructive hypoventilation to overt obstructive sleep apnea.

The behavioral phenotype of pediatric OSA differs from the adult phenotype in an important way. Adults with OSA classically present with daytime sleepiness. Children frequently present without overt sleepiness — instead, they present with hyperactivity, impulsivity, inattention, behavioral disinhibition, school underperformance, and emotional dysregulation. The pediatric clinical phenotype maps directly onto ADHD, and pediatric OSA has been called, with some justification, "the great masquerader" in childhood behavioral evaluations.

The strongest evidence base for the OSA-ADHD relationship in children comes from the Childhood Adenotonsillectomy Trial (CHAT), published in the New England Journal of Medicine in 2013. CHAT was a multicenter randomized controlled trial that enrolled 464 children aged 5 to 9 years with polysomnography-confirmed obstructive sleep apnea syndrome, randomizing them to either early adenotonsillectomy or watchful waiting with supportive care. The primary cognitive outcome — attention and executive function on formal neuropsychological testing — did not differ significantly between groups at seven-month follow-up.

That headline result has been frequently misquoted to suggest that adenotonsillectomy does not improve ADHD-like symptoms in children with OSA. The actual findings are more nuanced:

The clinical synthesis: adenotonsillectomy in children with OSA reliably improves sleep-disordered breathing and produces behavioral benefit observable to parents and teachers, even when formal cognitive testing does not capture it. In a child with both attentional symptoms and documented OSA, surgical treatment of the OSA is appropriate. If, after adequate OSA treatment, ADHD symptoms persist, a clean ADHD diagnostic evaluation can then be undertaken on a basis not confounded by sleep-disordered breathing.

Follow-up work to CHAT has examined longer-term outcomes and subgroups. Children with more severe baseline OSA, more severe baseline behavioral symptoms, or greater obesity tend to show larger surgical benefit. The watchful waiting arm's high spontaneous resolution rate means that, in mildly affected children, conservative management with reassessment is reasonable — but in symptomatic children with confirmed moderate-to-severe OSA, surgery is the standard of care.

Beyond CHAT, multiple smaller studies have shown that children with ADHD have higher rates of sleep-disordered breathing than the general pediatric population, and that treatment of the sleep disorder produces measurable improvement in inattention and hyperactivity ratings. A reasonable clinical estimate is that 20-30% of children carrying an ADHD diagnosis have a clinically meaningful sleep-disordered breathing component, ranging from primary snoring to overt OSA. For a discussion of how sleep disturbance more broadly intersects with ADHD in children, see our companion piece on ADHD and sleep.

Adult OSA: The Obesity-Snoring-Witnessed-Apnea Triad

The adult OSA presentation is anchored by a clinical triad: habitual loud snoring, witnessed apneas (typically reported by a bed partner), and excessive daytime sleepiness. When all three are present, the pretest probability of OSA is high. The triad is supported by anatomical and metabolic risk factors: obesity, large neck circumference, male sex, age greater than 50, hypertension, and craniofacial features that compromise the upper airway.

The cognitive phenotype of adult OSA is the same constellation that drives most adult ADHD evaluations: difficulty sustaining attention, distractibility, working memory complaints, slow processing speed, irritability, and what patients describe as "brain fog." Where the presentations differ is in the developmental history and the nocturnal symptom profile. Adult ADHD, by DSM criteria, has its onset in childhood — symptoms must be present before age 12 — and is a continuous pattern across the lifespan. Adult OSA, in contrast, typically has its onset in mid-adulthood, often coincident with weight gain, alcohol use, or the structural changes of aging.

The patient who presents at age 45 reporting that "my focus has been getting worse for the past few years," who snores, whose bed partner has noticed pauses in breathing, who has gained 20 pounds since their thirties, and whose blood pressure is creeping up, should not be initiated on stimulants without first being evaluated for OSA. The pretest probability of OSA in that clinical picture is high enough — and the consequences of treating with stimulants without addressing the underlying sleep disorder are concerning enough — that the screening burden is justified.

This pattern also intersects with our discussion of the natural course of ADHD pharmacology: genuine adult ADHD reflects a continuous developmental trajectory, not a mid-adult onset of attentional symptoms. A patient with apparently new-onset attentional symptoms in mid-adulthood warrants careful consideration of the differential — and OSA belongs near the top of that list.

The Co-Occurrence: When Both Are Present

The harder clinical situation is the patient with both conditions. Genuine ADHD — a neurodevelopmental disorder with onset in childhood, continuous through adulthood — does not protect against the development of obstructive sleep apnea. In fact, the two conditions co-occur at rates well above population baseline.

Several converging lines of evidence support this:

• Cross-sectional clinical studies consistently report that approximately one-third of adults presenting to ADHD clinics screen positive for OSA on validated questionnaires such as STOP-BANG, with confirmation rates on subsequent sleep study supporting that the screening signal reflects real disease
• Pediatric clinical samples show 20-30% rates of sleep-disordered breathing among children carrying ADHD diagnoses, substantially higher than the 1-5% pediatric OSA prevalence in the general population
• Genetic correlation analyses from large-scale cross-trait genome-wide association studies have identified shared genetic liability between ADHD and OSA, suggesting that the co-occurrence is not entirely explained by shared risk factors such as obesity
• Mendelian randomization approaches have provided some evidence for a causal relationship from ADHD-related traits to OSA risk, consistent with the clinical observation that ADHD-related lifestyle factors — irregular sleep, weight gain, alcohol use — may contribute to OSA development

The clinical consequence of comorbidity is that treating ADHD without treating OSA leaves a substantial portion of the cognitive burden unaddressed. Patients in this situation often report only partial response to stimulants — they get some attentional improvement, but the persistent "brain fog," daytime sleepiness, and irritability continue, because the upstream sleep pathology has not been corrected. When OSA is identified and treated, the residual ADHD often becomes more manageable, and stimulant therapy works better. The treatment-resistant ADHD patient is sometimes a treatment-resistant ADHD-plus-OSA patient.

Why Stimulants in Untreated OSA Is a Clinical Hazard

The decision to initiate stimulant therapy in a patient with undiagnosed OSA carries several specific risks that, taken together, justify the screening effort to identify OSA upstream of the prescription.

Stimulants do not treat OSA. The mechanism of obstructive sleep apnea is mechanical: upper airway collapse during sleep. Stimulant medications — methylphenidate, amphetamines, dextroamphetamine — increase dopaminergic and noradrenergic tone in the central nervous system. They do not affect upper airway patency during sleep, do not prevent oxyhemoglobin desaturation, and do not reduce the apnea-hypopnea index. A patient with OSA who is treated with stimulants continues to have OSA.

Stimulants partially mask the daytime sleepiness signal. One of the cardinal symptoms of OSA — the symptom that often eventually prompts sleep evaluation — is excessive daytime sleepiness. Stimulants reduce subjective sleepiness. The result is that a patient on stimulant therapy may feel "fine" during the day while continuing to have severe nighttime apneic episodes producing silent cardiovascular and metabolic damage. The diagnostic cue that would have prompted evaluation has been blunted by the medication.

Stimulants add cardiovascular load in a population already at elevated cardiovascular risk. Untreated OSA is an independent risk factor for hypertension, atrial fibrillation, heart failure, stroke, and cardiovascular mortality. The mechanisms include intermittent hypoxia, sympathetic activation, oxidative stress, and metabolic dysregulation. Stimulant medications produce modest but real increases in blood pressure and heart rate. The increment is well tolerated in patients without underlying cardiovascular disease — see our broader discussion of ADHD medication cardiovascular safety — but layering a stimulant-mediated blood pressure elevation onto an OSA-mediated cardiovascular stress is a different risk equation than stimulants in a metabolically healthy ADHD patient.

Stimulants taken late in the day worsen sleep fragmentation. Stimulants suppress sleep onset and reduce sleep efficiency when taken too close to bedtime. In a patient with OSA, who already has fragmented sleep, additional pharmacologic sleep disruption compounds the daytime cognitive consequences and may worsen the apparent cognitive burden the medication was prescribed to treat.

Treatment failure becomes diagnostically misleading. A patient with untreated OSA placed on stimulants for presumed ADHD who does not respond — or who responds partially and incompletely — is at risk of being escalated to higher doses, combined-mechanism agents, or augmentation strategies, when the actual problem is the unrecognized sleep disorder. The clinician interprets the treatment failure as a need for more aggressive ADHD pharmacotherapy, rather than as a signal that the diagnosis is incomplete.

None of this is an argument against stimulants in ADHD. It is an argument for diagnostic precision before prescription. For the broader case in favor of treating diagnosed ADHD, see the natural history of untreated ADHD and our discussion of ADHD and life expectancy.

Screening: The Practical Workup

The screening burden for OSA in patients being evaluated for ADHD is genuinely modest. A short sleep history added to the standard ADHD evaluation captures most of the diagnostic yield, and validated questionnaires can stratify risk for further workup.

Pediatric Screening

In children, the sleep history should ask specifically about:

• Habitual snoring — present on most nights, loud enough to be heard outside the room
• Witnessed apneas — parents reporting that the child stops breathing or gasps during sleep
• Restless sleep — frequent position changes, kicking, sweating
• Mouth breathing — both during sleep and during the day, particularly with adenoidal facies (open mouth posture, narrow palate, dental crowding)
• Adenotonsillar hypertrophy on physical examination — large tonsils visible on oropharyngeal exam, history of recurrent tonsillitis
• Morning headaches and dry mouth — both suggesting nocturnal hypoxemia or mouth breathing
• Daytime sleepiness — including paradoxical hyperactivity in young children
• Enuresis — secondary nocturnal enuresis can be associated with OSA

A child with multiple positive items, particularly habitual snoring with witnessed apneas or adenotonsillar hypertrophy, should be referred for pediatric sleep evaluation before stimulant initiation. The referral pathway typically includes pediatric otolaryngology evaluation for adenotonsillar assessment, and pediatric sleep medicine for polysomnography when indicated. Routine polysomnography for every pediatric ADHD evaluation is not currently recommended, but a low threshold for referral in symptomatic children is appropriate.

Adult Screening

In adults, the workhorse screening instrument is STOP-BANG, an eight-item questionnaire that captures both subjective symptoms and objective risk factors:

Interpretation: a score of 0-2 indicates low risk; 3-4 indicates intermediate risk; 5 or higher indicates high risk for moderate-to-severe OSA. STOP-BANG has higher sensitivity than the Epworth Sleepiness Scale for OSA detection, at the cost of lower specificity — meaning it captures more true cases at the expense of some false positives. In an ADHD evaluation, a STOP-BANG of 3 or higher should prompt referral for sleep study, particularly in patients with cardiovascular risk factors.

The Epworth Sleepiness Scale is a complementary instrument that quantifies subjective daytime sleepiness across eight scenarios. Scores above 10 suggest excessive daytime sleepiness, and scores above 16 are associated with severe sleepiness consistent with significant OSA. The Epworth is more specific for sleepiness as a symptom than for OSA as a diagnosis, and should not be used alone to screen for OSA.

Definitive diagnosis of OSA requires either in-laboratory polysomnography or home sleep apnea testing. Both produce the apnea-hypopnea index (AHI), the number of apneic or hypopneic events per hour of sleep, which is the standard severity metric:

• AHI < 5 — normal
• AHI 5-15 — mild OSA
• AHI 15-30 — moderate OSA
• AHI > 30 — severe OSA

Home sleep apnea testing is appropriate for many adults with high pretest probability of moderate-to-severe OSA and no significant cardiopulmonary comorbidities. In-laboratory polysomnography remains the gold standard and is preferred when the diagnosis is unclear, when central sleep apnea is suspected, in pediatric patients, and when initiating positive airway pressure therapy.

Treatment Ordering: Which to Treat First

The general principle in a patient with both confirmed OSA and presumed ADHD is to treat the OSA first, reassess, and then determine the need for ADHD pharmacotherapy. The rationale:

• OSA treatment alone — CPAP in adults, adenotonsillectomy in many pediatric cases — frequently produces substantial improvement in inattention, executive function, and emotional dysregulation
• If OSA treatment fully resolves the cognitive symptoms, the patient never had isolated ADHD — they had OSA-driven cognitive impairment, and stimulant initiation was avoided
• If OSA treatment produces partial improvement, residual ADHD symptoms can then be evaluated on a clean baseline, and stimulant therapy initiated with confidence that it is treating the right target
• If OSA treatment produces no improvement and the patient is adherent to therapy, this strengthens the case that ADHD is genuinely the primary diagnosis

In practical terms, "OSA first" usually means 6 to 12 weeks of adequate CPAP therapy with documented adherence and AHI reduction, followed by reassessment of ADHD symptoms. In pediatric patients, the time course after adenotonsillectomy is typically several months to allow full recovery and sleep normalization before re-evaluating attentional symptoms.

There are situations in which simultaneous initiation of ADHD therapy and OSA treatment is appropriate — most commonly when ADHD symptoms are causing severe functional impairment that cannot wait for OSA treatment to take effect. In these cases, treatment should proceed with explicit acknowledgment that the patient has dual diagnoses, with monitoring of cardiovascular parameters and ongoing assessment of which treatment is producing which benefit.

For patients with treatment-resistant ADHD — incomplete response to first-line stimulants, multiple medication trials without satisfactory outcome — sleep evaluation should be revisited if it was not done at baseline, or repeated if the initial evaluation was negative but clinical circumstances have changed (weight gain, new hypertension, new partner report of snoring).

A Practical Framework for the Clinician

Synthesizing the evidence and the clinical reality, a practical screening framework for ADHD evaluations might look as follows:

This framework is neither aggressive nor conservative — it represents the integration of sleep medicine into ADHD practice that the evidence supports. It does not require polysomnography for every patient. It does require sleep history for every patient and a low threshold for referral in those with risk factors.

The differential diagnosis of attentional complaints is broader than OSA. Major depression, generalized anxiety disorder, thyroid disease, substance use, and other conditions also produce attentional symptoms that can mimic ADHD. For discussions of those differentials, see our companion articles on depression versus ADHD and ADHD and the anxiety connection. OSA is one element of a comprehensive differential — but it is an element that is too often overlooked, and one with particularly clear treatment implications when identified.

The Family History Angle

ADHD is highly heritable — see our extended discussion of ADHD genetics and heritability. So is OSA, with familial aggregation reflecting shared craniofacial anatomy, body habitus, and ventilatory control phenotypes. In families with both ADHD and OSA running through multiple generations, the differential becomes particularly complex: a child of two parents, one with ADHD and one with OSA, who presents with attentional and behavioral symptoms could reasonably be either or both. A careful family history of sleep symptoms — snoring, witnessed apneas, dental appliance or CPAP use, weight history, hypertension — adds useful information to the standard family psychiatric history.

The shared genetic correlation between ADHD and OSA, identified in recent cross-trait GWAS work, also raises the possibility that some of the elevated comorbidity is not entirely explained by lifestyle mediators such as obesity. There may be shared developmental or physiological substrate that elevates risk for both conditions, though this remains an active research area rather than a finalized conclusion.

Lifestyle Factors That Cut Across Both Conditions

Several behaviors and conditions are independent risk factors for both worsening ADHD symptoms and worsening OSA, which makes them high-yield targets in patients with either or both diagnoses:

• Sleep timing and duration — irregular sleep schedules and chronic short sleep both worsen attentional function and reduce upper airway muscle tone, contributing to OSA severity
• Alcohol use — alcohol relaxes upper airway musculature and worsens OSA, and also exacerbates inattention and emotional dysregulation
• Weight management — weight loss improves OSA in many patients (with substantial AHI reduction in some), and is part of a broader lifestyle approach to ADHD; see ADHD and exercise evidence and ADHD diet and supplements
• Sedating medications taken at night — some sedating agents worsen upper airway collapse during sleep, complicating OSA
• Supine sleep position — for positional OSA, sleep position matters, and simple positional interventions can reduce AHI

These are not stand-alone treatments for OSA or ADHD, but they are appropriate components of the broader care plan and worth raising as part of the initial evaluation.

Common Clinical Scenarios

A few patterns recur frequently in practice. They are worth naming because they each illustrate the principles above.

The middle-aged man with new attention complaints. A 48-year-old male presents requesting evaluation for adult ADHD. He reports difficulty concentrating, irritability, and the subjective sense that his cognitive performance has declined over the past several years. He weighs 230 pounds at 5'10", reports loud snoring, and his wife has commented on pauses in his breathing during sleep. His blood pressure is 142/88. The pretest probability of OSA is high; the pretest probability of new-onset adult ADHD without childhood symptoms is low. STOP-BANG is 5. He should have a sleep study before any stimulant prescription is considered. If the sleep study confirms OSA and CPAP resolves his cognitive symptoms, the diagnosis was OSA, not ADHD.

The child with hyperactivity and habitual snoring. A 7-year-old presents for evaluation of inattention and hyperactivity, primarily noted at school. On history, parents report that he snores loudly every night, has been observed to have brief pauses in breathing, and is often described as "sweating in his sleep." Physical exam shows large tonsils. Pediatric otolaryngology referral and sleep evaluation should precede ADHD pharmacotherapy. If adenotonsillectomy is performed and behavior normalizes, the diagnosis was pediatric OSA. If symptoms persist after surgical treatment of OSA, ADHD can then be diagnosed on a clean basis.

The adult with confirmed ADHD whose stimulants stopped working. A 35-year-old patient with confirmed lifelong ADHD on stable stimulant therapy reports that her medication has felt "less effective" over the past year. She has gained 30 pounds since starting a new job, has been more sedentary, and her partner has recently commented on snoring. She is now requesting a stimulant dose increase. Before increasing the dose, OSA screening is appropriate — the loss of stimulant efficacy may reflect an emerging sleep disorder rather than a need for higher dose. STOP-BANG and a sleep history may identify the actual problem.

The treatment-resistant ADHD patient. A patient has tried multiple stimulants and atomoxetine without satisfactory response, with each medication producing modest improvement followed by perceived loss of effect. Sleep evaluation, if not previously done, is appropriate. Comorbid OSA is one of the more remediable causes of apparent ADHD treatment resistance.

What to Tell Patients

For patients being evaluated for ADHD or already on ADHD therapy, the messaging is straightforward and not anxiety-inducing:

"Attention symptoms can be driven by a number of different problems, and one of the most common — and most treatable — is obstructive sleep apnea. Apnea produces fragmented sleep, which makes you inattentive, irritable, and tired during the day. If you snore, if anyone has observed you stop breathing at night, if you wake up tired, if you have high blood pressure, or if you're carrying extra weight, we should rule out sleep apnea before we treat this as ADHD — or in addition to treating ADHD, if it turns out you have both. Sleep apnea is treatable, and the treatment often dramatically improves the daytime symptoms. It is one of the conditions where finding the right diagnosis really does change the outcome."

That conversation takes two minutes. It is among the highest-yield diagnostic conversations in adult attentional evaluations.

Frequently Asked Questions

How do I know whether I have ADHD or sleep apnea?

Key distinguishing features include age of onset (lifelong vs. more recent), nocturnal symptoms (snoring, gasping, witnessed apneas), daytime sleepiness, and risk factors (obesity, large neck circumference, hypertension; in children, adenotonsillar hypertrophy). Definitive diagnosis of OSA requires polysomnography. ADHD diagnosis is clinical and requires childhood onset and impairment across settings. The conditions can co-occur — roughly one in three adults with ADHD has OSA — so the question is not always either/or.

Can stimulants make sleep apnea worse?

Stimulants do not treat OSA — they do not affect upper airway collapse. They can add cardiovascular load to a population at elevated cardiovascular risk from untreated apnea, can fragment sleep further when taken late, and can mask the daytime sleepiness signal that would otherwise prompt sleep evaluation. They do not directly worsen the apneic events themselves, but they complicate the management picture meaningfully when OSA is unaddressed.

Will treating sleep apnea cure my ADHD?

If the cognitive symptoms were entirely OSA-driven, OSA treatment can resolve them — meaning the patient never had isolated ADHD. If genuine ADHD coexists with OSA, OSA treatment improves symptoms substantially but does not eliminate ADHD. Many patients in this situation find residual ADHD more manageable after OSA is treated, with stimulants working better and being better tolerated.

Should every child being evaluated for ADHD be screened for sleep apnea?

Every pediatric ADHD evaluation should include a sleep history. Routine polysomnography is not currently recommended for every evaluation, but a low threshold for sleep referral is appropriate in children with snoring, witnessed apneas, mouth breathing, adenotonsillar hypertrophy, or obesity.

Does adenotonsillectomy improve ADHD symptoms in children?

The CHAT trial showed that adenotonsillectomy in children with OSA did not significantly improve formal neuropsychological measures of attention and executive function, but it did produce significant improvement in caregiver- and teacher-rated behavior, including ADHD-relevant items, as well as quality of life and polysomnographic indices. In a child with both ADHD symptoms and documented OSA, surgical treatment of the OSA is appropriate, and behavioral improvement is the expected result.

What is STOP-BANG and how is it used?

STOP-BANG is an eight-item screening questionnaire (Snoring, Tired, Observed apneas, blood Pressure, BMI >35, Age >50, Neck >40 cm, Gender male). A score of 3 or higher indicates intermediate-to-high risk for OSA; 5 or higher indicates high risk for moderate-to-severe OSA. In adult ADHD evaluations, STOP-BANG 3 or higher should prompt sleep referral before stimulant initiation, particularly with cardiovascular risk factors.

Primary Reference

Further Reading

• ADHD and Sleep — the broader relationship between sleep disturbance and ADHD, including delayed sleep phase, restless legs, and stimulant-induced insomnia
• ADHD Medications and Cardiovascular Safety — what the large-scale evidence shows about stimulant cardiac risk, with implications for patients with comorbid OSA
• ADHD and Life Expectancy — the mortality data on untreated ADHD and the protective effect of evidence-based treatment
• Is ADHD Genetic? — the genetics literature, including the genetic correlation between ADHD and OSA
• ADHD and the Anxiety Connection — another major differential for attentional symptoms
• Depression vs. ADHD — the depressive differential for adult attentional complaints
• ADHD and Exercise: What the Evidence Shows — a lifestyle factor that intersects with both ADHD and OSA
• ADHD Diet and Supplements — the evidence on nutritional interventions
• Untreated ADHD: Adverse Outcomes — the case for diagnostic precision and timely treatment
• ADHD Pharmacology and the Natural Course — how stimulant therapy intersects with the developmental trajectory of ADHD
• Complete ADHD Guide — comprehensive resource on ADHD diagnosis, neurobiology, and treatment
• ADHD Psychiatrist NYC — evaluation and medication management for adults and adolescents with ADHD